Traumatic brain injury

Summary

Traumatic brain injury (MONDO:0858950) is a disease and 1,302 clinical trials. Top therapeutic interventions include amantadine, phenytoin, and mannitol. A subtype of brain injury — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 1,302

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	traumatic brain injury
Mondo ID	MONDO:0858950
DOID	DOID:0081292
Is cancer (heuristic)	no

Disease family

This is a subtype of brain injury. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › central nervous system disorder › brain disorder › brain injury › traumatic brain injury

Related subtypes (1): vascular brain injury

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1,302.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	819
PHASE2	93
PHASE3	51
PHASE4	40
PHASE1	39
PHASE1/PHASE2	24
EARLY_PHASE1	19
PHASE2/PHASE3	15

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05095857	PHASE4	RECRUITING	The Anaesthetic Ketamine as Treatment for Patients With Severe Acute Brain Injury
NCT06866691	PHASE4	RECRUITING	Seizure Prevention in Traumatic Brain Injury With Levetiracetam and Lacosamide
NCT07072624	PHASE4	RECRUITING	Early Post-Traumatic Seizures Prevention Trial (E-PTS Trial)
NCT07180277	PHASE4	NOT_YET_RECRUITING	Methylprednisolone for Moderate to Severe Traumatic Brain Injury
NCT07225101	PHASE4	RECRUITING	Evaluation of the Efficacy of STRATAFIX for Neurosurgical Cranial and Spine Procedures
NCT00163878	PHASE4	UNKNOWN	Is Sensory Stimulation Effective in Reducing Time Spent in a Coma or Vegetative State
NCT00204971	PHASE4	COMPLETED	Enteral Glutamine in Neurologically-injured Patients
NCT00254007	PHASE4	COMPLETED	Depression and Traumatic Brain Injury
NCT00462228	PHASE4	TERMINATED	Effect of Namenda on Short Term Memory and Attention in Patients With Mild to Moderate Traumatic Brain Injury
NCT00491192	PHASE4	UNKNOWN	Normothermia in Patients With Acute Cerebral Damage
NCT00505505	PHASE4	UNKNOWN	Intensive Insulin Therapy for Strict Glycemic Control in Neurosurgical Patients: Safety and Efficacy
NCT00618436	PHASE4	COMPLETED	Assess Safety and Efficacy of Levetiracetam(LEV;Keppra)for Seizure Prevention
NCT00693121	PHASE4	COMPLETED	Amantadine for Treatment of Symptoms of the Post-traumatic Confusional State
NCT00795587	PHASE4	TERMINATED	Comparison of 2 Doses of Mannitol on Post Traumatic Intracranial Hypertension and Cerebral Monitoring
NCT00957671	PHASE4	COMPLETED	Anterior Pituitary Hormone Replacement in Traumatic Brain Injury
NCT01470040	PHASE4	UNKNOWN	Does Discontinuation of Aspirin Treatment Following Head Trauma Decrease the Incidence of Chronic Subdural Hematoma?
NCT01606111	PHASE4	TERMINATED	The CAPTAIN Trial: Cerebrolysin Asian Pacific Trial in Acute Brain Injury and Neurorecovery
NCT01685476	PHASE4	COMPLETED	NIMI-NICU: Non Invasive Monitoring of the Intracranial Pressure - NeuroIntensive Care Unit
NCT01712477	PHASE4	TERMINATED	A Comparison of Propofol Versus Midazolam to Sedate Critically Brain Injury; Measurement of Cytokine Response and Assessment of Function
NCT01750268	PHASE4	COMPLETED	Topiramate Treatment of Hazardous and Harmful Alcohol Use in Veterans With TBI
NCT01799941	PHASE4	COMPLETED	Safety, Tolerability and Effectiveness of Nuedexta in the Treatment of Pseudobulbar Affect (PBA)
NCT01821690	PHASE4	COMPLETED	Buspirone for the Treatment of Traumatic Brain Injury (TBI) Irritability and Aggression
NCT01933217	PHASE4	COMPLETED	Methylphenidate for Attention Problems After Pediatric TBI
NCT02015949	PHASE4	COMPLETED	The Relationship Between Traumatic Brain Injury and Dopamine (a Chemical in the Brain)
NCT02071407	PHASE4	UNKNOWN	A Clinical Trial of the Effect of Midazolam on the Cerebral Metabolism and Inflammatory Response in Patients With Moderate and Severe Traumatic Brain Injury
NCT02130674	PHASE4	COMPLETED	Optimized Therapy in Severe Traumatic Brain Injured Patients
NCT02321761	PHASE4	UNKNOWN	Effect of Amantadine Administration on Spatial Functioning Following Traumatic Brain Injury
NCT02404779	PHASE4	UNKNOWN	Treatment of Intracranial Hypertension of Severe Tramatic Brain Injured Patients. Physiopathologic Effects of Neuromuscular Blocking Agents
NCT02712996	PHASE4	COMPLETED	Treatment of Traumatic Brain Injury (TBI)-Related Attention Deficits in Children
NCT03054285	PHASE4	UNKNOWN	Does Short-Term Anti-Seizure Prophylaxis After Traumatic Brain Injury Decrease Seizure Rates?
NCT03401515	PHASE4	COMPLETED	Using Propranolol in Traumatic Brain Injury to Reduce Sympathetic Storm Phenomenon
NCT03480880	PHASE4	COMPLETED	Bispectral Index Value Changes During Induction and Surgical Decompression in Head Injury Patients
NCT04006054	PHASE4	UNKNOWN	Study on Cerebral Protection of Dexmedetomidine for Patients With Traumatic Brain Injury
NCT04226365	PHASE4	TERMINATED	Pediatric Concussion Outcomes
NCT04239755	PHASE4	COMPLETED	Doxycycline in Acute Traumatic Brain Injury
NCT04487275	PHASE4	UNKNOWN	MLC901 for Moderate to Severe Traumatic Brain Injury (Specified Drug Code)
NCT04766281	PHASE4	UNKNOWN	MLC901 in Moderate Traumatic Brain Injury
NCT05058677	PHASE4	COMPLETED	Aerosolized Endotracheal Lidocaine to Avoid Intracranial Pressure Spikes in Patients With Severe Traumatic Brain Injury
NCT06429657	PHASE4	SUSPENDED	Ketamine for Sedation in Severe Traumatic Brain Injury
NCT07406555	PHASE4	COMPLETED	Comparison of C-Reactive Protein Levels in Traumatic Brain Injury Patients Undergoing Craniotomy With and Without Dexmedetomidine

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
AMANTADINE	4	15
PHENYTOIN	4	8
MANNITOL	4	6
PROPRANOLOL	4	6
RIVASTIGMINE	4	6
SORBITOL	4	6
LEVETIRACETAM	4	5
CITALOPRAM	4	4
FLORTAUCIPIR F 18	4	3
GLYBURIDE	4	3
SILDENAFIL CITRATE	4	3
ARMODAFINIL	4	2
BREXANOLONE	4	2
CYCLOSERINE	4	2
EPOETIN ALFA	4	2
LACOSAMIDE	4	2
LISDEXAMFETAMINE	4	2
MEMANTINE	4	2
METHYLPHENIDATE	4	2
THIOPENTAL	4	2
AMINO ACIDS	4	1
ATORVASTATIN CALCIUM	4	1
BACLOFEN	4	1
BARICITINIB	4	1
BIPERIDEN LACTATE	4	1
BROMOCRIPTINE	4	1
BROMOCRIPTINE MESYLATE	4	1
BUSPIRONE	4	1
CANDESARTAN CILEXETIL	4	1
CARBAMAZEPINE	4	1